This is the second placebo-controlled study to produce findings suggesting that atomoxetine is effective in providing continuous symptom relief in children with attention deficit hyperactivity disorder (ADHD). The
In a pooled analysis of placebo-controlled studies, patients taking Equetro, a carbamazepine extended-release capsule, who had been previously taking valproate or lithium (both with or without improvement of
The data shows that patients treated with olanzapine and fluoxetine capsules (OFC) not have fewer symptoms but also respond faster to the therapy than patients treated with lamotrigine.
The study, named COBRA, was designed to compare the efficacy and safety of telithromycin (Ketek) to other standard, single agent antibiotics, such as B-lactams, cephalosporins, macrolides, and quinolones,
Macugen will be first therapy in Brazil indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) regardless of lesion subtype or size. The drug, which was
VistaGen claims AV-101 (4-Cl-KYN) represents a potential first-in-class therapy for the multi-billion dollar neuronal disorder markets, including major disorders such as epilepsy and neuropathic pain. The preclinical data
This is the first of two phase I/II trials to be initiated using the NF-kappaB Decoy (NF-kB Decoy). A second trial will be conducted in Australia and Switzerland
The data suggests recombinant nematode anticoagulant protein c2 or rNAPc2, has an acceptable safety profile and is well tolerated in doses up to 10 microgram/kg, in patients with
Myriad’s technology using the single R-enantiomer of etodolac, biochemically triggers cellular suicide in lymphocytes. This technology will be used by Salmedix to further its clinical drug candidate SDX-101
The study of 554 patients found that nine months treatment with Spiriva (tiotropium) produced statistically and clinically significant improvements in health-related quality of life including sustained improvements in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.